Existing and emerging technologies for tumor genomic profiling
about
Patterns of Chromosomal Aberrations in Solid TumorsAdvances in the Molecular Analysis of Soft Tissue Tumors and Clinical ImplicationsThe possibility of clinical sequencing in the management of cancerTargeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and TreatmentCancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers.Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies.Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.Tumor genome analysis includes germline genome: are we ready for surprises?Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers.Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making.Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancerQuantification of lipid modified estrogenic derivative (ESC8) in rat plasma by LC-MS: application to a pharmacokinetic study.Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Data resources for the identification and interpretation of actionable mutations by clinicians.Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.New generation of breast cancer clinical trials implementing molecular profiling.Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer PanelPhysicians' attitudes about multiplex tumor genomic testing.New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.The 'omics' of adrenocortical tumours for personalized medicine.Personalized medicine in hematology - A landmark from bench to bedPrecision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.Molecular diagnostics in soft tissue sarcomas and gastrointestinal stromal tumors.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.Integrating genomics into prognostic models for AML.The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.Molecular Tumor Boards: Current Practice and Future Needs.An evaluation of synthetic and natural supravital stains for the cytological examination of dissociated cells in a microfluidic channel.Clinical Impact of Genomic Information in Pediatric Leukemia.Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing.In sickness and in health: context matters when considering potential benefits and risks of genome-wide sequencing.Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).
P2860
Q26786127-D3AB4B83-F5A2-4BE0-B9DE-68CC0C403A90Q27021848-10356314-42AE-4D4E-9C74-64E70895698BQ28072144-A14D11F9-7908-44CB-BDD7-D135A1F3C453Q28076462-C146019E-C78B-406F-A956-A60A68715094Q30794842-E9C5973B-5A0D-4B5B-BDBE-80B39BDEB124Q33420276-F9FF0A64-6833-44E1-B08E-F6FA841180F4Q33560928-AFE9E3A1-E1BC-4661-9570-7F5F2C471415Q33686447-442D7F05-C175-46DE-90B2-D410061305E3Q33873653-F9C57F36-B65A-44EF-ADD0-DF319AD1C426Q34248282-6E4B95F7-D6F7-4504-A134-A23CF7E33BC6Q34654793-3D21B41B-709F-4A82-80C9-3E6E6B0106BFQ35004182-09AED320-FD30-497D-8907-C6BD490ACFE6Q35107992-462B6E59-288B-48A4-A270-5A5EE873130BQ35213023-0A2095B1-3A55-429C-B7CD-C14EB381E345Q35453542-669C348A-0E43-4328-A8AB-7DBCE63F9309Q35580269-49848DE4-1290-42A2-BD9D-B3090F9C7C5DQ35846874-F6AD56A8-4383-4CA3-A1BB-4CD022142695Q36053456-8FE64A61-E06F-4FA1-AAAB-EF3034FF0548Q36288987-025033B7-1C06-46CB-85B5-9A266C127744Q36317783-F02AAB27-C4B5-4577-94FC-AB641A16AD1FQ36851421-9E043C97-3C2A-464E-8DA0-EF1D18EFB1F2Q37094064-86F9542C-94B5-4BF7-AD5D-7594B49DD62CQ37220383-02EC0F33-62D9-4650-8FAB-C6384E4DDC2BQ37324841-01BD142D-5BDD-41D4-BEB5-92D3E6BEC96EQ37712065-3AD7AC03-DF7E-4927-9024-B62D7FAF2487Q37724947-6D0CC79C-8893-49BC-B962-1A242B4964D9Q37725502-8C3D9D4D-7046-4BCD-B38C-428AE99A151CQ38184819-2C54E129-86BC-4483-B8DD-1DA9EDCF520DQ38263199-1ECD4C02-D211-440D-AA3E-90BCDC657990Q38364614-15E5FDEF-8302-4DFB-8575-A5E89E3E68B3Q38378763-471FB2E5-B66B-4081-899C-74A24D8BCFF3Q38513661-513A226F-3CAB-4633-A458-9F97A12B8A87Q39113916-3F788D7B-50A0-4A31-9786-C31F95427EC3Q42643276-FDDDBBEB-8911-4D8E-9F3E-2BF8949FA765Q42697732-2E1E5767-9070-4822-A5FE-14B8D2CE9D45Q46973328-EC4D368A-227C-4416-9E74-91C1EE919AE3Q47221791-33B40A8D-533C-4813-A4E6-84B790B015F5Q47238067-5B0E7C27-D1D9-4A61-BBA0-6846C7F1C7FBQ48150717-DD1CC49A-469C-44B4-AC90-84BEDC865942Q48873124-9618DB6C-0775-4738-AA50-4B2ACEB23631
P2860
Existing and emerging technologies for tumor genomic profiling
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Existing and emerging technologies for tumor genomic profiling
@en
Existing and emerging technologies for tumor genomic profiling.
@nl
type
label
Existing and emerging technologies for tumor genomic profiling
@en
Existing and emerging technologies for tumor genomic profiling.
@nl
prefLabel
Existing and emerging technologies for tumor genomic profiling
@en
Existing and emerging technologies for tumor genomic profiling.
@nl
P2860
P356
P1476
Existing and emerging technologies for tumor genomic profiling
@en
P2093
Laura E MacConaill
P2860
P304
P356
10.1200/JCO.2012.46.5948
P407
P577
2013-04-15T00:00:00Z